---
title: Oncology
description: Leverage comprehensive oncology data and insights to navigate market complexities and optimize drug commercialization strategies for improved patient access and engagement.
image: https://mckessoncompile.com/hubfs/Featured_Logo_McKessonCompile_Vertical_.png
---

# Uncover opportunities in oncology

## Comprehensive oncology data & market insights

Leverage real-world oncology data and healthcare analytics to navigate market complexities, refine provider targeting, and optimize oncology drug commercialization strategies.

### Understanding the evolving oncology market

The oncology market is evolving rapidly, projected to grow from $222.36 billion in 2023 to $628 billion by 2033. With over 200 cancer types and the increasing use of precision medicine, understanding the market is more critical- and more challenging- than ever.

 

 

 

## Key challenges for oncology brands

Navigating a complex market- oncology product teams face unique challenges in market visibility and healthcare provider (HCP) engagement:

 

## Medically Integrated Dispensing (MID)

networks reduce visibility into prescribing HCPs

## Centralized billing systems

reduce provider-specific insights

## Rapid advancements

are driving frequent changes in affiliations and reference data

## High-quality, integrated data is essential for oncology

Complex HCP-healthcare organization (HCO) relationships inherent in the oncology space necessitates accurate affiliations data so you can:

![oncology_graphic](https://mckessoncompile.com/hs-fs/hubfs/oncology_graphic.png?width=500&height=681&name=oncology_graphic.png "oncology_graphic")

![mck-Checkmark1](https://mckessoncompile.com/hs-fs/hubfs/mck-Checkmark1.png?width=50&height=50&name=mck-Checkmark1.png)

Improve incentive compensation allocation and gross-to-net analysis

![mck-Checkmark1](https://mckessoncompile.com/hs-fs/hubfs/mck-Checkmark1.png?width=50&height=50&name=mck-Checkmark1.png)

Optimize targeting of HCPs & HCOs

![mck-Checkmark1](https://mckessoncompile.com/hs-fs/hubfs/mck-Checkmark1.png?width=50&height=50&name=mck-Checkmark1.png)

More effectively deploy sales and marketing resources

![mck-Checkmark1](https://mckessoncompile.com/hs-fs/hubfs/mck-Checkmark1.png?width=50&height=50&name=mck-Checkmark1.png)

Optimize brand presence in light of treatment guidelines

![mck-Checkmark1](https://mckessoncompile.com/hs-fs/hubfs/mck-Checkmark1.png?width=50&height=50&name=mck-Checkmark1.png)

Prioritize efforts based on the changing market landscape

![mck-Checkmark1](https://mckessoncompile.com/hs-fs/hubfs/mck-Checkmark1.png?width=50&height=50&name=mck-Checkmark1.png)

Enhance visibility into infusion center activity

 

Click to view our case studies

#### Provider networks influence HCP behavior understanding IDN-level dynamics is key to unlocking the oncology market

## McKesson Compile's oncology solutions

#### **Gain insights with integrated data and expert analytics**

Gain deeper insights and remove knowledge gaps using provider reference and patient claims data crafted for oncology.

![data_analytics-1](https://mckessoncompile.com/hs-fs/hubfs/data_analytics-1.png?width=1294&height=468&name=data_analytics-1.png)

#### Data designed to drive success in oncology

Superior provider reference and affiliations data has the power to improve sales and marketing strategies. Provider 360 ReadyData™  includes advanced and accurate data on U.S. providers, organizations, and their corresponding affiliations so you can see the relationships between healthcare providers (HCPs), organizations (HCOs), and health systems. 

 

#### Specialty and treatment insights on oncology care teams

Provider 360 ReadyData includes derived attributes like practicing specialty and disease areas treated to help you identify influential stakeholders like nurse practitioners (NPs) and physician assistants (PAs) who are actively involved in oncology – along with the top cancer types they treat. These real-world insights help biopharma teams identify and engage key influencers across the oncology care journey.  

 

#### Infusion site insights for advanced therapy delivery  

Infusion centers are essential for delivering advanced care – particularly in oncology. Provider 360 ReadyData integrates data on over 8.5K+ infusion centers nationwide,  and captures key site-level details, providing insight into the center type, specialty, chair count, medications, and more – offering a clear view into where therapies are actually delivered.  

 

#### **McKesson Compile™ Provider 360 ReadyData delivers: **

## Proprietary affiliations scoring

to show HCP and HCO relationships

## Custom derived attributes

to provide insight into provider activity

## Monthly dataset updates

for real-time accuracy

 

Inclusion of multiple oncology sources provides strong coverage and accuracy of oncology HCP data

## 38.5K+

oncologists with an affiliation

## 99%+

coverage of oncology MDs & DOs*

## 95%

affiliations coverage of oncology MDs & DOs*

## 11.5K+

oncology NPs & PAs with an affiliation

## 3.5K+

infusion centers with an oncology or multi-specialty

*As compared to the NPPES universe, as of October 2024.​

 

“By leveraging the wealth of McKesson’s oncology data, we are helping to bridge the knowledge gaps that exist around where patients receive care and who their care teams are. Ultimately, we want to enable oncology brands to improve patient lives by getting their therapies to the patients that need them.”  

**Kirby Forlin **

Senior Vice President, Data Commercialization & Advanced Analytics, McKesson

 

## Proven strength in oncology: case studies

### HCP Targeting for urologic cancer

#### Situation

![tabler_chevron-down](https://mckessoncompile.com/hubfs/tabler_chevron-down.svg)

A biotech launching a new drug sought to target providers treating patients with a specific type of urologic cancer. Unfortunately, identifying the providers was not easy and required the usage of a combination of data on diagnoses, procedures, and treatment timelines.

#### Solution

![tabler_chevron-down](https://mckessoncompile.com/hubfs/tabler_chevron-down.svg)

The biotech chose McKesson Compile due to the strength of McKesson Compile claims data and incredible customer support. The Real-World Data Analytics (RWDA) team leveraged their expertise in oncology to triangulate insight from patient claims and medical codes found only in EHR data.

#### Results

![tabler_chevron-down](https://mckessoncompile.com/hubfs/tabler_chevron-down.svg)

McKesson Compile identified more than 20k high-value providers who were treating 270k patients for their launch target list. Using this target list the biotech was able to gain a nearly 20% higher adoption rate than similar drugs in market that used traditional targeting approaches.

### IDN identification for non-small cell lung cancer

#### Situation

![tabler_chevron-down](https://mckessoncompile.com/hubfs/tabler_chevron-down.svg)

The Market Access team at a large pharma company sought to improve patients’ access to treatment for a recently-launched NSCLC drug

​

- They wanted to identify the top treating IDNs and associated HCPs and pharmacies but were unable to correlate HCPs with organizational affiliations using their existing dataset​
- In addition, they had a blind spot when it came to some of their key accounts such as Kaiser and others where claims don’t go through switches

#### Solution

![tabler_chevron-down](https://mckessoncompile.com/hubfs/tabler_chevron-down.svg)

After a thorough evaluation of several vendors, the brand chose to partner with McKesson Compile due to:

- Strong coverage rates for NSCLC in McKesson Compile claims data, which included data otherwise excluded from switches, due to inclusion of Medicare data​
- Robust and up-to-date affiliations data that associated the HCP activity to the IDN level​
- **McKesson Compile delivered a view of IDNs with the highest NSCLC patients, including associated prescribers and pharmacies.**

#### Results

![tabler_chevron-down](https://mckessoncompile.com/hubfs/tabler_chevron-down.svg)

The robust affiliations data within Provider 360 ReadyData enabled the team to identify the top-treating IDNs, including those they didn’t previously have a view into, so that they could engage in conversations to improve patient access to their therapy.

## Resources & thought leadership

### [Report: The Who & Where of Oncology Care](https://hello.mckessoncompile.com/provider360-readydata?hsLang=en)

[Read](https://hello.mckessoncompile.com/provider360-readydata?hsLang=en)

[![np pa specializaiton report-1](https://mckessoncompile.com/hubfs/np%20pa%20specializaiton%20report-1.png) ](https://hello.mckessoncompile.com/provider360-readydata?hsLang=en)

### [White paper: Advancing Healthcare Provider Targeting in an Evolving Oncology Landscape](https://hello.mckessoncompile.com/oncology-hcp-targeting?hsLang=en)

[Read](https://hello.mckessoncompile.com/oncology-hcp-targeting?hsLang=en)

[![White paper cover-3-1](https://mckessoncompile.com/hubfs/White%20paper%20cover-3-1.png) ](https://hello.mckessoncompile.com/oncology-hcp-targeting?hsLang=en)

### [Webinar: Charting New Paths: Data and Analytics in the Evolving Oncology Landscape](https://pmsa.org/webinars/past-webinars/item/charting-new-paths-data-and-analytics-in-the-evolving-oncology-landscape)

[View Recording](https://pmsa.org/webinars/past-webinars/item/charting-new-paths-data-and-analytics-in-the-evolving-oncology-landscape)

[![Charting New Paths](https://mckessoncompile.com/hubfs/Charting%20New%20Paths.jpg) ](https://pmsa.org/webinars/past-webinars/item/charting-new-paths-data-and-analytics-in-the-evolving-oncology-landscape)

## Drive clarity and confidence with  McKesson Compile's data solutions, crafted for oncology brands

[ Get Started ](https://mckessoncompile.com/contact-us?hsLang=en)

---